A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Anova Innovation Limited
BeOne Medicines
Astellas Pharma Inc
Genmab
Actuate Therapeutics Inc.
ImmunityBio, Inc.
Dragonfly Therapeutics
Akeso
Engeneic Pty Limited
FutureGen Biopharmaceutical (Beijing) Co., Ltd
NovoCure Ltd.
Ascentage Pharma Group Inc.
NovoCure Ltd.
Inhibrx Biosciences, Inc
Tyligand Pharmaceuticals (Suzhou) Limited
Genfleet Therapeutics (Shanghai) Inc.
Laekna Limited
Merck Sharp & Dohme LLC
Faeth Therapeutics
ProDa BioTech, LLC
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
BeiGene
Mural Oncology, Inc
BeiGene
Trishula Therapeutics, Inc.
Innovent Biologics (Suzhou) Co. Ltd.
Merck Sharp & Dohme LLC
ImmunityBio, Inc.
ImmunityBio, Inc.
Nelum Corp
Purple Biotech Ltd.
Merck Sharp & Dohme LLC
Shanghai Yizhong Pharmaceutical Co., Ltd.
Arcus Biosciences, Inc.
EQRx International, Inc.
Sumitomo Pharma America, Inc.
Aravive, Inc.
Qilu Pharmaceutical Co., Ltd.
Shanghai Henlius Biotech
OncoSec Medical Incorporated
Nektar Therapeutics
Corcept Therapeutics
Jazz Pharmaceuticals
Scandion Oncology A/S
CSPC Ouyi Pharmaceutical Co., Ltd.
Eli Lilly and Company
NextCure, Inc.
Prescient Therapeutics, Ltd.